Artificial intelligence is transforming drug discovery by accelerating target identification, drug screening and personalisation of treatments. This Insight explores the impact of AI across the drug development pipeline and highlights key opportunities for securing IP protection in this fast-growing field.
The challenges of drug discovery
Discovering new treatments for disease is central to the pharmaceutical industry, but the process is notoriously time consuming, costly and uncertain. Identifying and screening candidate drugs involves evaluating huge libraries of molecules against biological targets, typically through a combination of in vitro and in vivo testing.
The problem is not a lack of data. In fact, the biomedical sciences generate vast volumes of data on how small molecules interact with proteins and other biological systems. The challenge lies in analysing this data efficiently to reveal promising therapeutic candidates.